Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its cystic fibrosis focus into endocrine disease treatments. The deal could add up to $5 billion in annual revenue through approved drug Palsonify and pipeline candidate Atumelnant. While Vertex's stock initially fell post-announcement, the au...

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%...

Crinetics Pharmaceuticals stock surged 98% this week following Vertex Pharmaceuticals' announcement of a $10 billion acquisition deal. Crinetics, which recently had its first FDA-approved drug (Palsonify) for acromegaly treatment, is now trading just below the $85 per share acquisition price. The deal allows Vertex to diversify beyond its cystic ...

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its dominant cystic fibrosis portfolio into rare endocrine disorders. The deal provides access to Palsonify for acromegaly and a pipeline asset for congenital adrenal hyperplasia, potentially adding $5 billion in peak annual revenue. While the...

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, representing a 102% premium to the pre-announcement price. The deal aims to expand Vertex beyond its core cystic fibrosis business into rare disease therapeutics, with immediate revenue from FDA-approved PALSONIFY for acromegaly and Phase 3 c...